Product Code: ETC13335257 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Non-Alcoholic Steatohepatitis Biomarkers Market was valued at USD 0.75 Billion in 2024 and is expected to reach USD 1.08 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is witnessing significant growth due to the rising prevalence of NASH, a condition characterized by liver inflammation and damage caused by a buildup of fat in the liver. Biomarkers play a crucial role in identifying and monitoring NASH progression, offering non-invasive methods for diagnosis and disease monitoring. The market is driven by the increasing demand for accurate diagnostic tools, the growing focus on personalized medicine, and advancements in biomarker research technologies. Key players in the market are investing in research and development activities to introduce novel biomarkers that can enhance diagnostic accuracy and facilitate early intervention strategies. Additionally, collaborations between pharmaceutical companies and research institutions are expected to further propel market growth in the coming years.
The Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is experiencing rapid growth due to the increasing prevalence of NASH worldwide. Key trends in this market include the development of non-invasive biomarkers for early detection and monitoring of NASH progression, as well as the focus on personalized medicine approaches for better patient outcomes. Opportunities in the market lie in the rising demand for accurate diagnostic tools, the potential for partnerships between pharmaceutical companies and diagnostic firms to advance biomarker research, and the growing investments in research and development activities to identify novel biomarkers for NASH. Overall, the market is poised for significant expansion as the need for effective diagnostic tools and treatments for NASH continues to rise.
The Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market faces several challenges, including the lack of standardized diagnostic criteria leading to variability in biomarker identification and validation. Additionally, the complexity of NASH pathogenesis and the diverse patient populations make it difficult to identify universal biomarkers that can accurately diagnose and monitor disease progression. Limited understanding of the underlying mechanisms of NASH further impedes the development of reliable biomarkers. Moreover, regulatory hurdles and the high cost associated with biomarker validation studies pose significant challenges in bringing new biomarkers to market. Overall, these challenges highlight the need for collaborative efforts among researchers, clinicians, and regulatory bodies to address the unmet needs in NASH biomarker development and advance the field towards personalized diagnostics and treatment strategies.
The Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is primarily driven by the increasing prevalence of NASH worldwide, coupled with the rising awareness about the disease and its potential complications. The growing emphasis on early diagnosis and monitoring of NASH to prevent disease progression and the development of effective treatment strategies is fueling the demand for biomarkers. Additionally, the surge in research and development activities aimed at identifying novel biomarkers for NASH diagnosis and prognosis is further propelling market growth. Furthermore, the escalating healthcare expenditure, advancements in diagnostic technologies, and favorable government initiatives promoting early disease detection are contributing to the expansion of the NASH biomarkers market globally.
Government policies related to the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market vary by country and region. In the United States, the FDA has issued guidelines for the development and approval of biomarkers for NASH diagnosis and monitoring, aiming to expedite the process of bringing new biomarkers to market. In Europe, regulatory bodies like the EMA also provide guidance on the validation and use of biomarkers for NASH. Additionally, governments in countries with a high prevalence of NASH, such as China and India, are focusing on implementing public health policies to address the rising burden of the disease, which may indirectly impact the market for NASH biomarkers by increasing demand for diagnostic tools and interventions. Overall, government policies play a crucial role in shaping the regulatory landscape and market dynamics of NASH biomarkers globally.
The Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is expected to witness significant growth in the coming years due to the rising prevalence of NASH worldwide and the increasing focus on early diagnosis and disease monitoring. The market is driven by the growing demand for non-invasive diagnostic tools and the development of advanced biomarkers for NASH detection. Additionally, the increasing investments in research and development activities to identify novel biomarkers and the rising awareness about the potential complications of NASH are contributing to market expansion. With ongoing advancements in technology and a shift towards personalized medicine, the Global NASH Biomarkers Market is poised for continued growth and innovation in the foreseeable future.
In the Global Non-Alcoholic Steatohepatitis Biomarkers Market, Asia is expected to witness significant growth due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in countries like China and India. North America is anticipated to hold a prominent market share, driven by the rising awareness about NASH and the presence of advanced healthcare infrastructure. Europe is also a key market, with a focus on research and development activities for biomarker discovery. The Middle East and Africa region is projected to show steady growth, supported by improving healthcare facilities. Latin America is likely to experience moderate growth due to the increasing adoption of diagnostic technologies. Overall, the global NASH biomarkers market is poised for expansion across all regions, with varying levels of opportunities and challenges.
Global Non-Alcoholic Steatohepatitis Biomarkers Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Non-Alcoholic Steatohepatitis Biomarkers Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 & 2031F |
3.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market - Industry Life Cycle |
3.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market - Porter's Five Forces |
3.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.8 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume Share, By Detection Method, 2021 & 2031F |
3.9 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Non-Alcoholic Steatohepatitis Biomarkers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Non-Alcoholic Steatohepatitis Biomarkers Market Trends |
6 Global Non-Alcoholic Steatohepatitis Biomarkers Market, 2021 - 2031 |
6.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Imaging Biomarkers, 2021 - 2031 |
6.1.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Genetic Biomarkers, 2021 - 2031 |
6.1.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Metabolic Biomarkers, 2021 - 2031 |
6.1.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Inflammatory Biomarkers, 2021 - 2031 |
6.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Fibrosis Assessment, 2021 - 2031 |
6.2.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Genetic Risk Factors, 2021 - 2031 |
6.2.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Lipid Profile, 2021 - 2031 |
6.2.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By CRP Levels, 2021 - 2031 |
6.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By MRI, 2021 - 2031 |
6.3.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Blood Tests, 2021 - 2031 |
6.3.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Mass Spectrometry, 2021 - 2031 |
6.3.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By ELISA, 2021 - 2031 |
6.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.4.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Research Institutes, 2021 - 2031 |
6.4.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Pharma Companies, 2021 - 2031 |
7 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
7.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
7.2 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
7.5 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
7.6 North America Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
8.1 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
8.4 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
8.5 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
8.6 Latin America (LATAM) Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
9.1 Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
9.4 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
9.5 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
9.6 Asia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
10.1 Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
10.4 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
10.5 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
10.6 Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
11.1 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
11.4 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
11.5 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
11.6 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Overview & Analysis |
12.1 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Type, 2021 - 2031 |
12.4 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Biomarker Type, 2021 - 2031 |
12.5 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By Detection Method, 2021 - 2031 |
12.6 Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Non-Alcoholic Steatohepatitis Biomarkers Market Key Performance Indicators |
14 Global Non-Alcoholic Steatohepatitis Biomarkers Market - Export/Import By Countries Assessment |
15 Global Non-Alcoholic Steatohepatitis Biomarkers Market - Opportunity Assessment |
15.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market Opportunity Assessment, By Type, 2021 & 2031F |
15.3 Global Non-Alcoholic Steatohepatitis Biomarkers Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
15.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market Opportunity Assessment, By Detection Method, 2021 & 2031F |
15.5 Global Non-Alcoholic Steatohepatitis Biomarkers Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Non-Alcoholic Steatohepatitis Biomarkers Market - Competitive Landscape |
16.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenue Share, By Companies, 2024 |
16.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |